ANO1/TMEM16A, a calcium-activated chloride channel (CaCC), has been shown to be highly amplified in several human cancers and recent evidence suggests ANO1 as a potential therapeutic target for cancer because down regulation of ANO1 reveals therapeutic advantages on HNSCC, breast, prostate and lung cancer treatment [6, 8, 9, 22]. This evidence concerns the gene ANO1 and lung carcinoma.